Access Solutions

Reimbursement Support

To speak live with one of our Specialists, call (866) 681-3261 from 6 a.m.–5 p.m. PT, Monday to Friday, fax (866) 681-3288 or visit RituxanAccessSolutions.com

Rituxan is now approved for retreatment at 6-month intervals Print Page

Patients can be effectively retreated every 6 months before signs and symptoms reappear

a
One course = 2 x 1000 mg intravenous infusions separated by 2 weeks.

Subsequent courses should be administered every 24 weeks or based on physician evaluation, but not sooner than every 16 weeks1

Next Section: Infusion Information

 

Indication

Rituxan® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

Important Safety Information

  • Rituxan has been associated with fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy (PML)
  • Hepatitis B reactivation, cardiac arrhythmias, and angina have also been observed
  • Patients should be closely observed for signs of infection if biologic agents and/or DMARDs other than methotrexate are used concomitantly
  • Common adverse reactions include infusion reactions and infections

Please see full prescribing information, including Boxed Warnings for additional safety information.

Reference
1.
Rituxan [package insert]. South San Francisco, CA: Biogen Idec, Inc. and Genentech USA, Inc.; October 2009.